Abstract
On the basis of large randomized clinical trials, pharmacological antagonists of HMG-CoA reductase (statins) have become increasingly used in clinical practice for the prevention of cardiovascular disease. Rosuvastatin was developed as a potent statin, which appeared to raise levels of HDL-cholesterol, in addition to marked reductions in levels of LDL-cholesterol. These effects on lipids are associated with a beneficial impact of rosuvastatin on progression of various stages of atherosclerosis and cardiovascular outcomes in clinical trials. The clinical experience of rosuvastatin will be reviewed in this article.
| Original language | English |
|---|---|
| Pages (from-to) | 1383-1390 |
| Number of pages | 8 |
| Journal | Expert Review of Cardiovascular Therapy |
| Volume | 9 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 2011 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- atherosclerosis
- cardiovascular disease
- clinical trials
- lipids
- risk factors
- rosuvastatin
Fingerprint
Dive into the research topics of 'Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver